Preprints with The Lancet is part of SSRN´s First Look, a place where journals identify content of interest prior to publication. Authors have opted in at submission to The Lancet family of journals to post their preprints on Preprints with The Lancet. The usual SSRN checks and a Lancet-specific check for appropriateness and transparency have been applied. Preprints available here are not Lancet publications or necessarily under review with a Lancet journal. These preprints are early stage research papers that have not been peer-reviewed. The findings should not be used for clinical or public health decision making and should not be presented to a lay audience without highlighting that they are preliminary and have not been peer-reviewed. For more information on this collaboration, see the comments published in The Lancet about the trial period, and our decision to make this a permanent offering, or visit The Lancet´s FAQ page, and for any feedback please contact firstname.lastname@example.org.
Prevalence of Obesity and Associated Complications in China: A Nationwide, Cross-Sectional, Observational, Real-World Study in 15.8 Million Adults
40 Pages Posted: 14 Dec 2022More...
Background: Studies of overweight/obesity prevalence in China have provided limited data regarding weight-related complications. We evaluated the prevalence of overweight/obesity and associated complications from a cross-sectional, health check-up database among a large, nationwide sample of 15.8 million adults in China.
Methods: Data were from Meinian Health check-up centres (519 in 243 cities). Eligibility criteria included participants with a routine check-up in 2019 (N=21 771 683), age ≥18 years, and complete height, weight, sex, and region data. Prevalence of overweight/obesity were calculated by age, sex, and region based on both the Chinese-specific and WHO body mass index (BMI) classification. Prevalence of obesity-related complications by BMI groups were calculated using logistic regression.
Findings: There were N=15 770 094 eligible participants (median age, 40 years; mean BMI 24·13 kg/m2; 52·79% male). By Chinese classification, 34·78% had overweight (BMI 24–<28 kg/m2) and 14·07% had obesity (BMI ≥28 kg/m2); standardised nationwide prevalences were similar (33·9% and 13·7%). Overweight/obesity were more prevalent in males vs females (standardised: overweight, 40·2% vs 27·4%; obesity, 17·6% vs 9·64%, respectively). Prevalences of assessed complications were higher in overweight/obese participants vs normal BMI (p<0·001 for trends). The most prevalent complications with overweight/obesity were fatty liver disease (overweight: 49·00%; obesity: 81·83%), prediabetes (34·51%; 45·92%), dyslipidaemia (31·30%; 42·42%), and hypertension (20·69%; 36·87%). Complication numbers increased with higher BMI.
Interpretation: Overweight/obesity and complications are highly prevalent among adults. These data may better inform management and prevention public health strategies in China.
Funding Statement: Supported by Novo Nordisk (China) Pharmaceuticals Co., Ltd
Declaration of Interests: Zewei Shen and Xuan Qi are employees of Novo Nordisk and are shareholders of Novo Nordisk Pharma. All other authors declare no competing interests [Yi Ning TBC].
Ethics Approval Statement: The study was approved by the Peking University Institutional Review Board (IRB00001052-19077).
Keywords: Obesity, Overweight, China, Prevalence, weight-related complications
Suggested Citation: Suggested Citation